Aprea Therapeutics, Inc. (APRE) Stock Forecast & Price Target

Aprea Therapeutics, Inc. (APRE) has an ST Score of 60.6 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate APRE a Buy. Our ST Score grades it B (60.6/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B-, Profitability B, Financial Strength A+, Momentum B-, Growth B.

Aprea Therapeutics, Inc. (APRE) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Aprea Therapeutics, Inc. (APRE) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Aprea Therapeutics, Inc. (APRE) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Aprea Therapeutics, Inc. (APRE) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

Aprea Therapeutics, Inc. (APRE) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.